BridgeBio

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in San Francisco, California, that specializes in developing treatments for diseases related to transthyretin (TTR) amyloidosis. The company is advancing AG10, an orally administered small molecule currently in phase 3 clinical trials, which aims to stabilize tetrameric TTR and interrupt the molecular processes leading to amyloidosis. Founded in 2013, Eidos Therapeutics operates as a subsidiary of BridgeBio Pharma, which focuses on creating genetically targeted therapies designed to address the underlying causes of various diseases. Through its innovative approach, Eidos Therapeutics seeks to provide potentially disease-modifying therapies to meet the significant medical needs associated with TTR-related conditions.

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in San Francisco, California, that specializes in developing treatments for diseases related to transthyretin (TTR) amyloidosis. The company is advancing AG10, an orally administered small molecule currently in phase 3 clinical trials, which aims to stabilize tetrameric TTR and interrupt the molecular processes leading to amyloidosis. Founded in 2013, Eidos Therapeutics operates as a subsidiary of BridgeBio Pharma, which focuses on creating genetically targeted therapies designed to address the underlying causes of various diseases. Through its innovative approach, Eidos Therapeutics seeks to provide potentially disease-modifying therapies to meet the significant medical needs associated with TTR-related conditions.

QED Therapeutics, a biotechnology company based in San Francisco, specializes in developing precision medicines for disorders associated with Fibroblast growth factors and their receptors (FGFR). Founded in 2017, the company operates as a subsidiary of BridgeBio Pharma. Its primary focus is on infigratinib, a leading FGFR kinase inhibitor that has demonstrated significant clinical efficacy in patients with chemotherapy-refractory cholangiocarcinoma featuring FGFR2 fusions. Additionally, QED Therapeutics is exploring the use of infigratinib in preclinical studies for the treatment of achondroplasia and aims to expand its development efforts to include various FGFR-driven tumor types and rare diseases.

PellePharm, Inc. is a biopharmaceutical company based in Menlo Park, California, focused on researching and developing skin cancer therapeutics. The company is working on patidegib, a novel topical gel formulation that acts as a hedgehog pathway inhibitor, specifically designed to treat basal cell carcinomas (BCCs) and basal cell nevus syndrome, a rare genetic skin disease. By repurposing existing oral medications into a topical application, PellePharm aims to mitigate tumor burden and improve patient quality of life. The treatment seeks to reduce the need for invasive surgeries and the associated complications, such as scarring. Currently, patidegib is undergoing phase 2 clinical trials to assess its effectiveness in treating sporadic BCCs. Since its incorporation in 2012, PellePharm has remained dedicated to advancing innovative solutions in skin cancer care.

MyoKardia, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for rare cardiovascular diseases. Founded in 2012 and headquartered in Brisbane, California, the company primarily addresses heritable cardiomyopathies and genetically-driven heart failure caused by biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently in Phase III trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, an orally administered small molecule that has completed Phase I and IIa trials for dilated cardiomyopathy. The company also has several preclinical programs, including MYK-224 for HCM, ACT-1 for diastolic dysfunction, and LUS-1 for diastolic dysfunction. As of late 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.

MyoKardia, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for rare cardiovascular diseases. Founded in 2012 and headquartered in Brisbane, California, the company primarily addresses heritable cardiomyopathies and genetically-driven heart failure caused by biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently in Phase III trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, an orally administered small molecule that has completed Phase I and IIa trials for dilated cardiomyopathy. The company also has several preclinical programs, including MYK-224 for HCM, ACT-1 for diastolic dysfunction, and LUS-1 for diastolic dysfunction. As of late 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.